[ad_1]

atlanta, April 16, 2024 /PRNewswire/ — Annoviant™, Inc. is a pioneering company with the breakthrough TxGuard™ technology platform for soft tissue healing, currently focused on the cardiovascular field. $2.99 ​​million Authorization (SBIR phase 2b) from the National Institutes of Health (NIH). This grant is designed to advance the development and commercialization of the innovative TxGuard™ pulmonary valved conduit. Building on a Phase II NIH grant secured in 2021, this funding represents a significant step forward in Annoviant’s mission to transform the landscape of pediatric cardiac care.

Annoviant’s patented TxGuard™ is a technology in conduit replacement to treat congenital heart disease (CHD), the most prevalent birth defect and leading cause of birth-related deaths worldwide. We are at the forefront of innovation. CHD includes a variety of abnormalities that interfere with blood flow to or from the heart, and it affects approximately 40,000 babies each year in the United States and 1.35 million babies worldwide. With an estimated 2.9 million CHD patients in the United States alone, the need for advanced solutions is paramount.

Addressing significant shortcomings observed in current commercial devices, TxGuard™ offers unparalleled clinical benefits, particularly resistance to calcification, thrombosis, infection, and integration into host cells. This cutting-edge technology heralds a new era in pediatric cardiac intervention, providing a durable pulmonary valved graft that adapts and regenerates with the patient, eliminating the need for multiple reoperations over a lifetime. minimize sex.

“We are pleased to receive this additional grant from the NIH with matching funds from our esteemed investors. “This is an important milestone for us.” Ajay HaudePhD, MBA, Co-Founder and CEO of Annoviant.

Pediatric patients with CHD often undergo multiple cardiovascular surgeries over their lifetime, and associated costs total billions of dollars to the U.S. healthcare industry. TxGuard™ offers an innovative solution to this ongoing challenge, promising increased durability and reduced healthcare burden for both patients and healthcare professionals.

Dr. Naren VyavahaleAnnoviant’s CTO and co-founder, Ph.D., commented: “Pediatric CHD patients need medical devices that can evolve with them into adulthood. After 15 years of dedicated research, we developed TxGuard™ technology to address this important need. With NIH Phase IIb funding, we look forward to further improving the pulmonary valved conduit for the benefit of CHD patients. ”

About Anobiant
Founded in 2018, Annoviant™ is a pioneering healthcare innovation company dedicated to developing innovative medical devices that improve and save lives. Annoviant is driven by our co-founders’ personal experiences and an unwavering dedication to positively impacting the lives and outcomes of patients with congenital heart disease (CHD). At the heart of Annoviant’s mission is a patented breakthrough innovation designed to heal and adapt with patients battling life-threatening congenital heart disease and other soft tissue applications. TxGuard™. This patented portfolio of innovative devices addresses numerous clinical challenges and offers the potential to significantly reduce healthcare costs by eliminating the need for repeat surgeries. Annoviant actively collaborates with a diverse network of leading research institutes and industry partners across the country to advance innovative solutions. For more information, please visit Annoviant.com.

NIH (National Institutes of Health) Research reported in this news release was supported by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) under award number 2R44HL147771-04. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

For media inquiries or further information, please contact:

Anobiant media relations
[email protected]

Source Anobiant

[ad_2]

Source link